

To estimate the **Potential Peak Sales** for mosunetuzumab-axgb (Lunsumio) in the indication of relapsed or refractory follicular lymphoma (R/R FL) in the US, EU5 (Germany, France, Italy, Spain, UK), China, and Japan, as well as the **\$ value of a 1% share of treated patients** in these geographies, we need to follow a structured approach. Since specific data on patient numbers, pricing, and market dynamics for mosunetuzumab-axgb are not fully public or provided in the query, I will outline the methodology and use reasonable assumptions based on available oncology market data and analogous drugs. The results will be approximate and should be refined with more precise data if available.

Step 1: Define the Indication and Patient Population

Mosunetuzumab-axgb is approved for adult patients with relapsed or refractory follicular lymphoma (R/R FL) after two or more lines of systemic therapy. Follicular lymphoma is a type of non-Hodgkin lymphoma (NHL), and R/R FL represents a subset of patients who have failed prior treatments.

- **Prevalence of Follicular Lymphoma:** FL accounts for approximately 20-30% of NHL cases. The incidence of NHL varies by geography, with higher rates in developed regions like the US and EU5.
- **R/R FL Population:** Only a subset of FL patients progress to R/R status after 2+ lines of therapy. This is typically estimated as 20-30% of FL patients over time, though exact numbers depend on survival rates and treatment patterns.
- **Estimates of Eligible Patients:** Based on literature and market reports for NHL and FL:
 - **US:** ~15,000-20,000 R/R FL patients eligible for 3rd-line or later therapy annually.
 - **EU5:** ~12,000-18,000 patients (adjusted for population size relative to the US).
 - **Japan:** ~3,000-5,000 patients (smaller population, lower incidence).
 - **China:** ~10,000-15,000 patients (large population but lower diagnosis rates and access to advanced therapies).

Total eligible patients across these geographies: ~40,000-58,000 annually.

Step 2: Market Share Assumption

The query assumes a **20% to 30% share of treated patients** for mosunetuzumab-axgb. This accounts for competition from other therapies in R/R FL, such as CAR-T therapies (e.g., Yescarta, Kymriah), other bispecific antibodies, and standard-of-care options like chemotherapy or PI3K inhibitors.

- At 20% share: ~8,000-11,600 treated patients.
- At 30% share: ~12,000-17,400 treated patients.

Step 3: Pricing and Treatment Cost

Mosunetuzumab-axgb is a novel bispecific antibody therapy, and pricing for such drugs in oncology (e.g., Blincyto, a similar bispecific) typically ranges from \$100,000 to \$200,000 per patient per year in the US, depending on dosing and duration. Pricing in other regions is often lower due to healthcare system differences:

- **US:** ~\$150,000 per patient per year.
- **EU5:** ~\$100,000 per patient per year (discounted due to price negotiations).
- **Japan:** ~\$120,000 per patient per year (similar to EU5 but with some variation).
- **China:** ~\$50,000 per patient per year (significantly lower due to affordability and market access constraints).

For simplicity, we can assume a weighted average cost of ~\$100,000 per patient per year across all geographies, adjusted for regional pricing differences in final calculations.

Step 4: Calculate Potential Peak Sales

Peak sales are calculated as: **Number of treated patients × Annual cost per patient.**

At 20% Market Share (~8,000-11,600 patients):

- **US:** 3,000-4,000 patients × \$150,000 = **\$450M - \$600M.**
- **EU5:** 2,400-3,600 patients × \$100,000 = **\$240M - \$360M.**
- **Japan:** 600-1,000 patients × \$120,000 = **\$72M - \$120M.**
- **China:** 2,000-3,000 patients × \$50,000 = **\$100M - \$150M.**
- **Total Peak Sales at 20% Share: \$862M - \$1,230M.**

At 30% Market Share (~12,000-17,400 patients):

- **US:** 4,500-6,000 patients × \$150,000 = **\$675M - \$900M.**
- **EU5:** 3,600-5,400 patients × \$100,000 = **\$360M - \$540M.**
- **Japan:** 900-1,500 patients × \$120,000 = **\$108M - \$180M.**
- **China:** 3,000-4,500 patients × \$50,000 = **\$150M - \$225M.**
- **Total Peak Sales at 30% Share: \$1,293M - \$1,845M.**

Thus, **Potential Peak Sales** for mosunetuzumab-axgb in R/R FL across the specified geographies are approximately:

- **\$0.86B - \$1.23B at 20% share.**
- **\$1.29B - \$1.85B at 30% share.**

Step 5: Calculate \$ Value of 1% Share of Treated Patients

A 1% share of treated patients corresponds to 1% of the eligible patient population (~40,000-58,000), i.e., 400-580 patients.

- **US:** 150-200 patients × \$150,000 = **\$22.5M - \$30M.**

- **EU5:** 120-180 patients × \$100,000 = **\$12M - \$18M.**

- **Japan:** 30-50 patients × \$120,000 = **\$3.6M - \$6M.**

- **China:** 100-150 patients × \$50,000 = **\$5M - \$7.5M.**

- **Total \$ Value of 1% Share:** **\$43.1M - \$61.5M.**

Thus, the **\$ value of a 1% share of treated patients** across these geographies is approximately **\$43M - \$62M.**

Key Assumptions and Caveats

1. **Patient Population:** Estimates are based on general NHL/FL epidemiology and may vary with real-world data on R/R FL after 2+ lines of therapy.

2. **Pricing:** Assumed costs are based on analogous therapies and may differ based on actual pricing for mosunetuzumab-axgb, reimbursement policies, and treatment duration.

3. **Market Share:** 20-30% share assumes moderate uptake; actual penetration depends on clinical outcomes, competition (e.g., CAR-T therapies), and payer dynamics.

4. **Access:** China's lower pricing and access barriers may reduce overall sales potential compared to the US and EU5.

Final Answer

- **Potential Peak Sales for mosunetuzumab-axgb in R/R FL (US, EU5, China, Japan):**

- At 20% share: **\$0.86B - \$1.23B.**

- At 30% share: **\$1.29B - \$1.85B.**

- **\$ Value of 1% Share of Treated Patients:** **\$43M - \$62M.**

These figures are estimates and should be validated with primary market data, clinical trial outcomes, and updated pricing information for more accuracy.